相关临床试验
144
21 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1955
进行中（未招募）
11
7.6%
已完成
96
66.7%
Enrolling By Invitation
2
1.4%
尚未招募
8
5.6%
招募中
15
10.4%
暂停
1
0.7%
终止
3
2.1%
Unknown
2
1.4%
撤回
6
4.2%
暂无批准数据
- An international research team has identified a synthetic sugar molecule that could support vaccines, antibody therapies and rapid diagnostics for Candida auris, an emerging multidrug-resistant fungus. - The chemically synthesised β-mannan tetrasaccharide, absent from human cells, was linked to a carrier protein to create a glycoconjugate vaccine candidate. - In a mouse infection model, vaccination generated antibodies that recognised the synthetic sugar and reduced fungal load in the kidneys and spleen, with protective activity also shown in passively immunised mice. - The same antibody platform produced a prototype lateral flow test for detecting multiple Candida species, though all approaches remain in preclinical development.
- A University of Exeter study of more than 1,100 insulin-treated patients found a type 1 genetic risk score identified hidden type 1 diabetes in 16% of those with a negative MODY genetic test. - The approach will now be adopted as part of NHS testing, enabling laboratories to provide a diagnosis where results previously returned without explanation. - Researchers say the score reduces the need for expensive further testing and helps clinicians distinguish MODY from type 1 diabetes to target individualized treatment. - The study, published in Diabetes Care, was funded by Diabetes UK and the Medical Research Council and supported by NIHR Exeter Biomedical Research Centre.
- The CycleTrack study, led by the universities of Bristol and Exeter, will create the world's largest biobank of dried menstrual fluid samples to improve understanding of heavy menstrual bleeding and related conditions. - Heavy menstrual bleeding affects up to half of women worldwide, yet researchers say menstrual health remains poorly understood due to a lack of high-quality data. - The study will recruit thousands of participants from the Children of the 90s and Born in Bradford birth cohorts, collecting real-time symptom data and menstrual fluid samples over three cycles. - Researchers hope the findings will enable earlier diagnosis, more personalised treatment, and new ways to identify health risks such as iron deficiency.
- Illumina has launched TruPath Genome, a whole-genome sequencing workflow that eliminates traditional library prep and delivers 16 genomes per day in about 10 minutes of hands-on time. - The platform fully phases up to 98% of genes and extends accurate variant calling into difficult-to-map 'dark regions' of the genome using on-flow-cell library preparation and DRAGEN algorithms. - Data presented at AGBT showed TruPath Genome resolving challenging loci including the SMN1/SMN2 region in spinal muscular atrophy and genes linked to inherited adrenal disorders. - Broad Clinical Labs is among the first adopters, while more than 30 early access customers including GeneDx, Rady Children's Hospital and Baylor College of Medicine piloted the technology over 16 months.
- The Medical Research Council (MRC) is investing £9.7 million to establish ten Regional Accounts for Clinical Researchers (RACR) across the UK. - The initiative brings together more than 50 research organisations and over 60 NHS organisations across England, Scotland, Wales and Northern Ireland. - The programme will deliver flexible, tailored support to more than 190 clinicians at critical career "pinch points" over the next two years. - The University of Exeter and Royal Devon University Healthcare NHS Foundation Trust will join the Great Western Clinical Research Alliance to support clinical academics.
- At the European Society of Human Genetics 2026 conference in Gothenburg, Sweden, more than 6,000 global leaders gathered to discuss advances in genomic medicine. - Professor Emma Baple, medical lead for the NHS England Rapid Genome Sequencing Service for Critically Unwell Children, highlighted the clinical benefits of whole-genome sequencing. - The meeting emphasized the rapid progress in sequencing technologies and the growing integration of genomic insights into routine clinical practice. - Speakers shared real-world experiences implementing genomics at scale, underscoring how genomic medicine could evolve to improve outcomes for critically ill patients.
- University of Exeter researchers found that genetic variant disease risk is often lower in the general population than previously reported, raising concerns about overdiagnosis in newborn genome screening programs. - Analysis of nearly one million volunteers across UK Biobank and All of Us datasets showed weaker links between genetic variants and disease compared to studies conducted in high-risk populations. - The team focused on more than 50 genes across 15 diseases included in large-scale newborn screening trials, finding the biggest overdiagnosis risk when disease stems from loss of just one gene copy. - Researchers call for further studies and more accurate risk estimates before widespread rollout, emphasizing the profound impact on families told their baby is at high risk of developing disease.
- The ELSA study successfully screened over 17,000 UK children aged 3-13 for type 1 diabetes autoantibodies, identifying 160 children with early-stage disease and preventing emergency diagnoses. - Researchers developed a genetic risk score that identifies adults in the top 10% as having eight times higher risk of early-stage type 1 diabetes, enabling targeted screening for new immunotherapy treatments. - ELSA 2 launches today to expand screening to 30,000 additional children aged 2-17 across the UK, establishing NHS Early-Stage Type 1 Diabetes Clinics for comprehensive family support. - The breakthrough immunotherapy teplizumab, recently licensed in the UK, can delay insulin dependency by up to three years when administered before symptoms develop.
- A phase 3 randomized controlled trial of 820 adults found that VER-01, a standardized full-spectrum cannabis extract, reduced chronic low back pain by 1.9 points versus 1.4 for placebo on the numeric rating scale. - The study demonstrated that 54% of VER-01 participants achieved at least 30% pain reduction compared to 40% with placebo, while also improving sleep quality and physical function significantly. - VER-01 was generally well-tolerated with no signs of dependence or withdrawal symptoms, positioning it as a potential nonaddictive alternative to opioids and NSAIDs for chronic pain management. - The standardized cannabis extract showed particular efficacy in patients with neuropathic pain components, delivering an additional 1.5-point reduction in pain scores.
- A collaborative team from University of Dundee, GSK, and University of Exeter has received £17.9 million from Wellcome to develop new antifungal treatments over five years. - The project targets Cryptococcus neoformans, which causes meningitis and kills approximately 180,000 HIV patients annually, and Candida auris, a climate change-linked pathogen with over 40% fatality rates. - The initiative aims to generate two pre-clinical drug candidates for cryptococcal meningitis with broad-spectrum potential, addressing critical gaps in antifungal drug development. - Fungal infections cause around 2.5 million deaths worldwide annually, yet the drug development pipeline remains severely limited with increasing resistance and poor diagnostics.
